A 6-week individualized smoking cessation program led to greater quit rates among patients with RA when compared with usual care.
Day Safety Update Submitted to FDA ORCA-OL Long-Term Safety Trial Successfully ConcludedDSMC Completes Final Review of Cytisinicline, Finds ...
A new peer-reviewed study in the journal Marketing Science finds that direct-to-consumer (DTC) advertising for prescription smoking-cessation drugs meaningfully reduces cigarette use. At the same time ...
Providing tobacco-cessation support is a key element of the World Health Organization (WHO) Framework Convention on Tobacco Control (FCTC). 4 This landmark 2005 treaty outlined evidence-based policies ...
Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is ...
Achieve Life Sciences Inc. (NASDAQ:ACHV) is moving closer to a pivotal moment as it seeks FDA approval for cytisinicline, a potential first new smoking cessation therapy in nearly two decades, ...
Adult patients with severe CRSwNP treated with tezepelumab continued to receive benefit 24 weeks after treatment cessation.
One of Only Nine Therapies Chosen for the Inaugural FDA Commissioner’s National Priority Voucher for E-cigarette or Vaping CessationConference ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback